ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Also, decreased level of miR30a has revealed an increase in the level of BCR-ABL that consequently enhances cell proliferation.71 Moreover, targeting miR30a enhances imatinib activity against CML mediated by Becline1and autophagy protein 5.72 Upregulation of miR29a-3p and miR660-5p target and downregulateTET2 and EPAS1, respectively, that in turn confer TKI-resistance to CML-LSC.